Finally, we examined the GSE2603 dataset and validated that EZH2 expression was negatively correlated with bone metastasis-free survival in breast cancer patients (r = −0.2394, P = 0.03) (Fig. 6d), suggesting that high EZH2 expression in primary breast tumors produces a high risk of developing bone metastasis in patients. The gene discussed is EZH2; the disease is breast cancer.